LG Chem Becomes First Korean Company to Enter Canadian Dermal Filler Market
2024.12.12■ LG Chem launches hyaluronic acid filler ‘YVOIRE’ in Canada, a strategic hub in the Americas region
■ Canadian filler market projected to grow from KRW 400 billion in 2023 to KRW 700 billion by 2030
LG Chem has become the first Korean company in the dermal filler industry to establish a significant presence in Canada.
On the 12th, LG Chem announced that it successfully held a launch event for its hyaluronic acid fillers, ‘YVOIRE Classic Plus’ and ‘YVOIRE Volume Plus,’ in Toronto, Canada. Over 500 local aesthetic professionals and stakeholders attended the event.
In response to North America’s growing interest in Korean medical aesthetic products and technologies, LG Chem launched YVOIRE as the first Korean filler in the Canadian market. The company aims to position YVOIRE as a leading global filler brand.
LG Chem obtained approval for medical product sales in Canada this January, leveraging clinical trial data from major European countries that share similar multicultural demographics with Canada.
As part of its strategic preparation for entry into the Canadian market, a key hub for expanding market share in North and South America, LG Chem has been laying the groundwork for several years. Currently, LG Chem exports YVOIRE to seven countries in the Americas, including Canada, Brazil, Mexico, and Argentina. Through successful commercialization in Canada, LG Chem aims to further strengthen its influence in the Americas market.
According to a report by U.S.-based market research firm Grand View Research, the Canadian dermal filler market is projected to grow from KRW 400 billion in 2023 to KRW 700 billion by 2030. LG Chem plans to aggressively penetrate the market by introducing its premium filler brand ‘Y-Solution’ and aims to achieve a double-digit market share.
Jennifer Rho, Head of LG Chem’s Aesthetic Business Unit, stated, “To support the global expansion of YVOIRE, which is loved by customers in over 30 countries, we have been making proactive investments, including clinical development in Europe and China.” She added, “We will continue to enhance the global brand reputation of YVOIRE by offering differentiated customer experiences to clients in Korea and worldwide.”